FDA Approves First Monoclonal Antibody for COPD
Journal: Nature Reviews Drug Discovery
Author: Asher Mullard, USA
This paper discusses the FDA approval of dupilumab (Dupixent), the first monoclonal antibody for treating chronic obstructive pulmonary disease (COPD). The drug, developed by Regeneron and Sanofi, targets patients with an eosinophilic phenotype and is expected to benefit around 300,000 adults in the U.S.
Expanding the Genetic Alphabet to Create New Proteins
Journal: Science
Author: Dr. Floyd Romesberg, The Scripps Research Institute, USA
Scientists from the Scripps Research Institute have expanded the genetic alphabet to create novel proteins, enabling easier addition of non-canonical amino acids to proteins. This development enhances our ability to design new proteins with potential applications in drug development and protein engineering.
CRISPR-Based Gene Editing Therapies in Clinical Trials
Journal: Nature Medicine
Author: Dr. Jennifer Doudna, University of California, Berkeley, USA
The potential for CRISPR-based therapies to treat a variety of genetic conditions has profound implications. As these therapies are refined, they could lead to more effective treatments for diseases like cancers and genetic disorders .
Neurotechnology race ramps up, but fundamental questions remain
Journal: Nature
Author: Bec Crew, Senior Editor, Nature Index, USA
With rapid advancements in neuroscience, AI and brain-computer interface (BCI) technologies are gaining attention for their potential in brain research. However, fundamental questions about how core brain functions operate at cellular and molecular levels remain unresolved. While these technologies are expected to significantly impact the treatment of neurological disorders in the future, more research and funding are required.
